CRL Charles River Laboratories International, Inc. Common Stock
NYSE · Life Sciences Tools & Services · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 5, 2026
$290,19
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$146,2052tyg. minimum
$303,3152tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Przychody (TTM)
$4.00B
Twoje odznaki
Zakres 52 tyg.
$146–$303
Ocena Analityków
BUY
Cena Docelowa
$305
P/E
-60.5
ROE
-7.7%
Marża Zysku Netto
-6.0%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
CRL Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$290.19
Kapitalizacja Rynkowa (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Przychody (TTM)
$4.00B
ROE (TTM)
-7.7%
D/E Dług/Kapitał (MRQ)
0.0
Zakres 52 tyg.
$146–$303
CRL Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O Charles River Laboratories International, Inc. Common Stock Przegląd firmy z Wikipedii
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaLife Sciences Tools & Services
pracownicy18 300
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$4.02B2016-12-31 → 2025-12-27
EPS$-2.912016-12-31 → 2025-12-27
Wolny przepływ pieniężny$518M2016-12-31 → 2025-12-27
Marża netto-6.0%2016-12-31 → 2025-12-27
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | CRL | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -60.5średnia z 5 lat ≈191.6 | ≈191.6 | · | · | |
| P/S (TTM) | 3.5średnia z 5 lat ≈3.2 | ≈3.2 | 4.9 | Niedowartościowany | |
| P/B (MRQ) | 4.9średnia z 5 lat ≈4.1 | ≈4.1 | 3.6 | Wartość godziwa | |
| EV / EBITDA | 32.8średnia z 5 lat ≈16.9 | ≈16.9 | 25.4 | Niedowartościowany | |
| Cena / FCF (TTM) | 37.4średnia z 5 lat ≈28.8 | ≈28.8 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 23.8średnia z 5 lat ≈17.3 | ≈17.3 | 26.2 | Niedowartościowany | |
| EV / Revenue (EV / Przychody) | 3.5średnia z 5 lat ≈3.1 | ≈3.1 | · | · | |
| EV / FCF | 27.1średnia z 5 lat ≈28.3 | ≈28.3 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 5.4 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | CRL | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 2.3%średnia z 5 lat ≈10.8% | ≈10.8% | 12.1% | Zgodnie z | |
| Marża EBITDA (TTM) | 9.7%średnia z 5 lat ≈19.2% | ≈19.2% | 14.8% | Najwyższa półka | |
| Pretax Margin (Marża przed opodatkowaniem) | -2.5%średnia z 5 lat ≈8.6% | ≈8.6% | 12.4% | Słaby | |
| Marża Zysku Netto (TTM) | -6.0%średnia z 5 lat ≈6.3% | ≈6.3% | 10.8% | Słaby | |
| ROA (TTM) | -3.2%średnia z 5 lat ≈3.4% | ≈3.4% | 2.0% | Słaby | |
| ROE (TTM) | -7.7%średnia z 5 lat ≈9.0% | ≈9.0% | 3.3% | Słaby | |
| ROIC | 1.1%średnia z 5 lat ≈10.7% | ≈10.7% | 3.0% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | CRL | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.0średnia z 5 lat ≈0.0 | ≈0.0 | 0.1 | Niski dług | |
| Wskaźnik bieżący (MRQ) | 1.3średnia z 5 lat ≈1.4 | ≈1.4 | 1.8 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 0.8średnia z 5 lat ≈0.9 | ≈0.9 | 1.2 | Niska płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | CRL | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | -0.85%średnia z 5 lat ≈6.9% | ≈6.9% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 0.33%średnia z 5 lat ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 6.6% | · | · | · | |
| EPS YoY | -97.8%średnia z 5 lat ≈-17.6% | ≈-17.6% | · | · | |
| Net Income YoY (Zysk Netto R/R) | -95.3%średnia z 5 lat ≈-16.5% | ≈-16.5% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | -70.3% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | -61.6% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | CRL | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.5średnia z 5 lat ≈0.5 | ≈0.5 | 0.5 | Zgodnie z | |
| Receivables Turnover (Rotacja należności) | 5.6średnia z 5 lat ≈5.5 | ≈5.5 | 5.6 | Zgodnie z | |
| Revenue / Employee (Przychody / pracownika) | ≈$219.4K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
8.9%
Następny raport
Lis 03, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 12, 2026 | $3.02 | $2.76 | 9.2% |
| 31 marca 2026 | $2.06 | $1.96 | 5.0% | |
| 31 grudnia 2025 | $2.39 | $2.37 | 0.98% | |
| 30 września 2025 | $2.43 | $2.36 | 2.9% | |
| 30 czerwca 2025 | $3.12 | $2.52 | 23.7% | |
| 31 marca 2025 | $2.34 | $2.10 | 11.4% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.30 | $67.69 | $70.06 | $58.42 | $50.21 | $42.49 | $33.40 | $27.33 | $22.05 | $17.67 | $15.70 | $14.20 | |
| Revenue / Share | $81.01 | $78.45 | $80.26 | $77.50 | $68.84 | $57.77 | $52.75 | $46.23 | $38.25 | $35.06 | · | · | |
| Cash Flow / Share | $14.88 | $14.23 | $13.29 | $12.08 | $14.79 | $10.80 | $9.68 | $9.00 | $6.55 | $6.26 | · | · | |
| Cash / Share | $4.34 | $3.81 | $5.39 | $4.59 | $4.78 | $4.59 | $4.86 | $4.05 | $3.46 | $2.48 | $2.53 | $3.38 | |
| EPS (TTM) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | · | 49,213,000 | 49,149,000 | 50,677,000 | · | 51,394,000 | 51,551,000 | 51,437,000 | · | 51,283,000 | 51,097,000 | · | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | · | 49,426,000 | 49,316,000 | 50,853,000 | · | 51,583,000 | 51,846,000 | 51,842,000 | · | 51,607,000 | 51,428,000 | · | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.50 | $61.05 | · | $69.20 | $68.14 | $65.04 | · | $73.97 | $72.13 | $70.67 | · | $64.45 | · | · | $51.63 | |
| Revenue / Share | $20.91 | $20.34 | · | $20.33 | $20.93 | $19.35 | · | $19.58 | $19.79 | $19.51 | · | $19.89 | $20.02 | · | $19.29 | |
| Cash Flow / Share | · | $0.84 | · | · | · | $3.38 | · | · | · | $2.51 | · | · | $2.13 | · | · | |
| Cash / Share | $4.02 | $3.98 | · | $4.21 | $3.72 | $4.67 | · | $4.11 | $3.47 | $6.35 | · | $3.06 | · | · | $3.81 | |
| EPS (TTM) | $-4.80 | $-3.71 | · | $-1.51 | $-1.28 | $-0.60 | · | $8.01 | $8.37 | $8.52 | · | $9.25 | $9.68 | · | $8.49 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.00B | $4.03B | · | $4.02B | $4.03B | $4.02B | · | $4.06B | $4.08B | $4.11B | · | $4.22B | $4.09B | · | $3.78B | |
| Net Income TTM | $-238M | $-185M | · | $-82M | $-67M | $-25M | · | $424M | $442M | $444M | · | $475M | $496M | · | $436M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | -44.9 | -42.9 | · | -98.4 | -117.2 | -259.2 | · | 24.8 | 24.7 | 31.8 | · | 21.2 | 20.8 | · | 22.1 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | 2.5 | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.6 | 3.3 | · | 2.3 | 2.5 | · | 2.5 | |
| Earnings Yield | -2.2% | -2.3% | · | -1.0% | -0.85% | -0.39% | · | 4.0% | 4.0% | 3.1% | · | 4.7% | 4.8% | · | 4.5% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Przychody | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Marża Operacyjna % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Zysk netto | $-144M | $22M | $475M | $486M | $391M |
| Rozwodniony EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Wskaźnik | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Wskaźnik bieżący | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Wskaźnik Szybkości | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
| Wskaźnik | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $518M | $502M | $365M | $295M | $532M |
Właściciele instytucjonalni (13F) 607 emitentów · $13.6B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
607
Wartość posiadanych akcji
$13.6B
Nowe pozycje
74
Zamknięte pozycje
62
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 74 (-17 vs poprzedni kw.) | 62 (-19 vs poprzedni kw.) | 193 (0 vs poprzedni kw.) | 204 (+13 vs poprzedni kw.) | +2.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1 174 373 670 | 5 887 175 | 8,66% | Akcje |
| FMR LLC | $961 533 236 | 4 239 752 | 7,09% | Akcje |
| BlackRock, Inc. | $861 475 349 | 3 798 560 | 6,35% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $714 227 026 | 3 149 288 | 5,26% | Akcje |
| Invesco Ltd. | $676 919 391 | 2 984 785 | 4,99% | Akcje |
| HARRIS ASSOCIATES L P | $508 269 048 | 2 241 144 | 3,75% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501 427 927 | 2 210 979 | 3,70% | Akcje |
| Allspring Global Investments Holdings, LLC | $436 473 035 | 1 905 247 | 3,22% | Akcje |
| STATE STREET CORP | $422 800 968 | 1 864 284 | 3,12% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $373 848 597 | 1 648 450 | 2,76% | Akcje |
| ARIEL INVESTMENTS, LLC | $341 587 697 | 1 506 185 | 2,52% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $295 598 099 | 1 305 738 | 2,18% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $292 210 525 | 1 288 463 | 2,15% | Akcje |
| CITADEL ADVISORS LLC | $270 696 771 | 1 193 601 | 2,00% | Akcje |
| BANK OF AMERICA CORP /DE/ | $265 930 779 | 1 172 586 | 1,96% | Akcje |
| EARNEST PARTNERS LLC | $254 007 295 | 1 120 011 | 1,87% | Akcje |
| AMERIPRISE FINANCIAL INC | $199 834 979 | 881 189 | 1,47% | Akcje |
| NEUBERGER BERMAN GROUP LLC | $195 633 630 | 862 704 | 1,44% | Akcje |
| SEI INVESTMENTS CO | $184 499 540 | 813 530 | 1,36% | Akcje |
| MORGAN STANLEY | $181 542 851 | 800 487 | 1,34% | Akcje |
| Clearbridge Investments, LLC | $177 185 527 | 781 276 | 1,31% | Akcje |
| COOKE & BIELER LP | $171 369 328 | 755 630 | 1,26% | Akcje |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $157 642 604 | 682 173 | 1,16% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $150 762 735 | 664 768 | 1,11% | Akcje |
| UBS Group AG | $146 675 752 | 646 747 | 1,08% | Akcje |
| GOLDMAN SACHS GROUP INC | $145 100 822 | 639 803 | 1,07% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $110 324 717 | 486 462 | 0,81% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $106 061 291 | 467 663 | 0,78% | Akcje |
| BANK OF MONTREAL /CAN/ | $104 270 783 | 459 768 | 0,77% | Akcje |
| NORTHERN TRUST CORP | $101 169 205 | 446 092 | 0,75% | Akcje |
| Gotham Asset Management, LLC | $98 233 181 | 433 146 | 0,72% | Akcje |
| Amundi | $93 528 650 | 412 402 | 0,69% | Akcje |
| NORGES BANK | $83 921 372 | 370 040 | 0,62% | Akcje |
| MARSHALL WACE, LLP | $77 787 835 | 342 995 | 0,57% | Akcje |
| Iron Triangle Partners LP | $75 748 141 | 379 728 | 0,56% | Akcje |
| CITIGROUP INC | $71 714 853 | 316 217 | 0,53% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $69 108 583 | 304 725 | 0,51% | Akcje |
| Bank of New York Mellon Corp | $69 054 385 | 304 486 | 0,51% | Akcje |
| Boston Trust Walden Corp | $65 523 486 | 288 917 | 0,48% | Akcje |
| JPMORGAN CHASE & CO | $65 085 033 | 286 317 | 0,48% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $64 615 913 | 374 585 | 0,48% | Akcje |
| SNYDER CAPITAL MANAGEMENT L P | $63 899 443 | 281 756 | 0,47% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63 174 169 | 278 558 | 0,47% | Akcje |
| DEUTSCHE BANK AG\ | $62 723 084 | 276 569 | 0,46% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $61 384 115 | 270 665 | 0,45% | Akcje |
| PRIMECAP MANAGEMENT CO/CA/ | $60 523 448 | 266 870 | 0,45% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $58 234 910 | 256 779 | 0,43% | Akcje |
| Meridiem Capital Partners LP | $56 012 367 | 246 979 | 0,41% | Akcje |
| Alyeska Investment Group, L.P. | $53 295 650 | 235 000 | 0,39% | Akcje |
| LOOMIS SAYLES & CO L P | $50 725 593 | 223 668 | 0,37% | Akcje |
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 zgłoszenia | 4 sierpnia 2011 | · | Pierwotne zgłoszenie | · | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 zgłoszenia | 9 lutego 2011 | · | Pierwotne zgłoszenie | · | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 zgłoszenia | 7 grudnia 2010 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 16 czerwca 2010 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 7 czerwca 2010 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 5 maja 2010 | · | Pierwotne zgłoszenie | Kampania zarządu | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 57 insiderów · 23 dyrektorzy generalni · 29 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer | 19 sierpnia 2026 G | 35 485 | 0 | 1 | $-1 819 350 |
| Glenn Coleman | EVP & Chief Financial Officer | 30 września 2026 P | 27 762 | 1 | 0 | $2 974 |
| Flavia Pease | Corporate Executive VP & CFO | 31 maja 2025 F | 17 297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 3 marca 2022 M | 25 819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 lipca 2018 M | 17 155 | 0 | 0 | $0 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | 19 sierpnia 2026 M | 4 807 | 0 | 3 | $-2 965 466 |
| Mark Mintz | EVP, Chief Information Officer | 31 maja 2026 F | 9 546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 7 listopada 2024 G | 23 337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 1 czerwca 2020 A | 3 171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 maja 2020 A | 224 478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 1 października 2016 F | 5 599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 2 marca 2016 S | 11 034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 lutego 2015 M | 14 094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 sierpnia 2010 F | 74 390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 lutego 2010 A | 31 897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 sierpnia 2007 F | 37 109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 czerwca 2007 M | 11 750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 1 maja 2007 A | 6 262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 2 kwietnia 2007 A | 11 500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 2 kwietnia 2007 F | 12 713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 lutego 2007 A | 12 710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 lutego 2006 S | 16 134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 grudnia 2004 M | 8 000 | 0 | 0 | $0 |
| James C Foster | Dyrektor | 25 sierpnia 2026 M | 31 596 | 0 | 3 | $-34 844 875 |
| Nancy C Andrews | Dyrektor | 18 sierpnia 2026 M | 1 438 | 0 | 1 | $-163 443 |
| Steven Barg | Dyrektor | 2 czerwca 2026 A | 3 287 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Dyrektor | 8 maja 2026 A | 4 563 | 0 | 0 | $0 |
| George Llado | Dyrektor | 8 maja 2026 A | 6 702 | 0 | 0 | $0 |
| Abraham Ceesay | Dyrektor | 8 maja 2026 A | 2 384 | 0 | 0 | $0 |
| Mark J Enyedy | Dyrektor | 8 maja 2026 A | 2 384 | 0 | 0 | $0 |
| Paul W Graves | Dyrektor | 8 maja 2026 A | 2 384 | 0 | 0 | $0 |
| Craig B. Thompson | Dyrektor | 8 maja 2026 A | 3 851 | 0 | 0 | $0 |
| Martin Mackay | Dyrektor | 8 maja 2026 A | 17 137 | 0 | 0 | $0 |
| Virginia M Wilson | Dyrektor | 8 maja 2026 A | 6 349 | 0 | 0 | $0 |
| George Massaro | Dyrektor | 15 maja 2025 S | 5 575 | 0 | 0 | $0 |
| Richard F Wallman | Dyrektor | 7 listopada 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Dyrektor | 13 maja 2024 A | 7 894 | 0 | 0 | $0 |
| Robert J Bertolini | Dyrektor | 13 maja 2024 A | 32 802 | 0 | 0 | $0 |
| Richard C Reese | Dyrektor | 15 maja 2023 A | 65 541 | 0 | 0 | $0 |
| George M Milne JR | Dyrektor | 7 maja 2021 A | 29 079 | 0 | 0 | $0 |
| Stephen D Chubb | Dyrektor | 23 lutego 2021 M | 40 529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Dyrektor | 22 maja 2019 A | 3 886 | 0 | 0 | $0 |
| William Waltrip | Dyrektor | 5 grudnia 2012 S | 21 830 | 0 | 0 | $0 |
| Samuel O Thier MD | Dyrektor | 9 maja 2012 A | 18 230 | 0 | 0 | $0 |
| Douglas E Rogers | Dyrektor | 7 maja 2010 A | 12 859 | 0 | 0 | $0 |
| Nancy T Chang | Dyrektor | 7 maja 2010 A | 31 010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Dyrektor | 13 lutego 2006 A | · | 0 | 0 | $0 |
| Walter S Nimmo | Dyrektor | 25 lutego 2005 S | 149 447 | 0 | 0 | $0 |
| John Urquhart | Dyrektor | 17 lutego 2005 A | 11 738 | 0 | 0 | $0 |
| Louise S Mccrary | Dyrektor | 17 lutego 2005 A | · | 0 | 0 | $0 |
| Robert Cawthorn | Dyrektor | 2 czerwca 2004 G | 278 600 | 0 | 0 | $0 |
| Joseph W Laplume | · | 10 sierpnia 2026 G | 31 041 | 1 | 1 | $-61 124 |
| Victoria L Creamer | · | 6 sierpnia 2026 M | 30 051 | 0 | 1 | $-1 083 030 |
| Michael Gunnar Knell | · | 6 sierpnia 2026 M | 11 852 | 0 | 9 | $-1 730 250 |
| Thomas F Ackerman | · | 29 lutego 2016 F | 111 346 | 0 | 0 | $0 |
| Dennis R Shaughnessy | · | 29 listopada 2004 G | 35 511 | 0 | 0 | $0 |
| Michael F Ankcorn | · | 4 listopada 2004 S | 0 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 106 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| EPSB · Harbor ETF Trust | 2,15% | 443 NS | 31 lipca 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,73% | 51 248 SH | 1 października 2026 | Dziennie |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,71% | 5 092 NS | 31 lipca 2026 | N-PORT |
| EPSV · Harbor ETF Trust | 1,59% | 415 NS | 31 lipca 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1,44% | 291 NS | 31 lipca 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 1,09% | 4 303 NS | 31 lipca 2026 | N-PORT |
| IBB · iShares Trust | 0,96% | 363 741 SH | 11 września 2026 | Dziennie |
| LSEQ · Harbor ETF Trust | 0,93% | 614 NS | 31 lipca 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,74% | 2 375 NS | 31 lipca 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0,69% | 22 191 SH | 1 października 2026 | Dziennie |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,66% | 259 NS | 31 lipca 2026 | N-PORT |
| PALC · Pacer Funds Trust | 0,61% | 5 509 NS | 31 lipca 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,49% | 12 141 NS | 31 lipca 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,45% | 6 439 NS | 31 lipca 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,44% | 24 918 SH | 1 października 2026 | Dziennie |
| FFSM · FIDELITY COVINGTON TRUST | 0,40% | 25 814 NS | 31 lipca 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,34% | 209 615 NS | 31 lipca 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 7 783 NS | 31 lipca 2026 | N-PORT |
| ESML · iShares Trust | 0,24% | 25 082 SH | 11 września 2026 | Dziennie |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 20 898 NS | 31 lipca 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,24% | 25 378 NS | 31 lipca 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,23% | 13 626 NS | 31 lipca 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701 498 SH | 19 sierpnia 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,22% | 147 648 NS | 31 lipca 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 702 813 SH | 1 października 2026 | Dziennie |
| IYH · iShares Trust | 0,22% | 28 670 SH | 11 września 2026 | Dziennie |
| SMMD · iShares Trust | 0,19% | 26 152 SH | 11 września 2026 | Dziennie |
| IXJ · iShares Trust | 0,17% | 25 598 SH | 11 września 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,17% | 23 486 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,16% | 148 331 SH | 19 sierpnia 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,15% | 2 111 NS | 31 lipca 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 3 646 NS | 31 lipca 2026 | N-PORT |
| WSML · iShares Trust | 0,14% | 6 080 SH | 11 września 2026 | Dziennie |
| IWS · iShares Trust | 0,13% | 73 404 SH | 11 września 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1 102 914 SH | 19 sierpnia 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,13% | 947 NS | 31 lipca 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,12% | 42 976 NS | 31 lipca 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 2 764 SH | 1 października 2026 | Dziennie |
| IEUS · iShares Trust | 0,10% | 5 579 SH | 11 września 2026 | Dziennie |
| IWR · iShares Trust | 0,10% | 200 615 SH | 11 września 2026 | Dziennie |
| RECS · Columbia ETF Trust I | 0,10% | 23 999 NS | 31 lipca 2026 | N-PORT |
| XOEF · iShares Trust | 0,07% | 61 SH | 11 września 2026 | Dziennie |
| DFUV · Dimensional ETF Trust | 0,06% | 41 352 NS | 31 lipca 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 1 302 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,05% | 106 991 NS | 31 lipca 2026 | N-PORT |
| IVE · iShares Trust | 0,04% | 79 930 SH | 11 września 2026 | Dziennie |
| IUSV · iShares Trust | 0,04% | 42 675 SH | 11 września 2026 | Dziennie |
| SCZ · iShares Trust | 0,04% | 171 786 SH | 11 września 2026 | Dziennie |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 174 824 SH | 19 sierpnia 2026 | Dziennie |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,04% | 11 139 SH | 19 sierpnia 2026 | Dziennie |
| DCOR · Dimensional ETF Trust | 0,04% | 5 545 NS | 31 lipca 2026 | N-PORT |
| IWD · iShares Trust | 0,04% | 108 791 SH | 11 września 2026 | Dziennie |
| CHRI · Global X Funds | 0,03% | 11 NS | 31 lipca 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 29 579 SH | 19 sierpnia 2026 | Dziennie |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 9 073 SH | 1 października 2026 | Dziennie |
| TOPC · iShares Trust | 0,03% | 32 SH | 11 września 2026 | Dziennie |
| DFSU · Dimensional ETF Trust | 0,02% | 2 431 NS | 31 lipca 2026 | N-PORT |
| XVV · iShares Trust | 0,02% | 576 SH | 11 września 2026 | Dziennie |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,02% | 1 252 SH | 1 października 2026 | Dziennie |
| PBP · Invesco Exchange-Traded Fund Trust | 0,02% | 287 SH | 30 września 2026 | Dziennie |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,02% | 7 028 SH | 1 października 2026 | Dziennie |
| EGLE · Global X Funds | 0,02% | 2 NS | 31 lipca 2026 | N-PORT |
| IVV · iShares Trust | 0,02% | 607 129 SH | 11 września 2026 | Dziennie |
| VOO · VANGUARD INDEX FUNDS | 0,02% | 1 250 774 SH | 19 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1 530 468 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 8 168 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 4 112 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,02% | 11 106 SH | 19 sierpnia 2026 | Dziennie |
| IWV · iShares Trust | 0,02% | 14 165 SH | 11 września 2026 | Dziennie |
| IWB · iShares Trust | 0,02% | 33 863 SH | 11 września 2026 | Dziennie |
| XRMI · Global X Funds | 0,02% | 41 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 9 979 NS | 31 lipca 2026 | N-PORT |
| XYLD · Global X Funds | 0,02% | 2 566 NS | 31 lipca 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2 018 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,02% | 63 582 SH | 11 września 2026 | Dziennie |
| PHDG · Invesco Actively Managed Exchange-T… | 0,02% | 38 SH | 1 października 2026 | Dziennie |
| PTLC · Pacer Funds Trust | 0,02% | 2 492 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,02% | 1 620 NS | 31 lipca 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,02% | 14 645 NS | 31 lipca 2026 | N-PORT |
| XYLG · Global X Funds | 0,02% | 45 NS | 31 lipca 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,02% | 182 NS | 31 lipca 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,02% | 1 141 NS | 31 lipca 2026 | N-PORT |
| XTR · Global X Funds | 0,01% | 3 NS | 31 lipca 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,01% | 332 NS | 31 lipca 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,01% | 3 766 NS | 31 lipca 2026 | N-PORT |
| IEUR · iShares Trust | 0,01% | 37 473 SH | 11 września 2026 | Dziennie |
| XCLR · Global X Funds | 0,01% | 2 NS | 31 lipca 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1 973 SH | 1 października 2026 | Dziennie |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 110 946 SH | 19 sierpnia 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 77 796 SH | 19 sierpnia 2026 | Dziennie |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 447 656 SH | 19 sierpnia 2026 | Dziennie |
| IDEV · iShares Trust | 0,01% | 52 174 SH | 11 września 2026 | Dziennie |
| IEFA · iShares Trust | 0,00% | 272 340 SH | 11 września 2026 | Dziennie |
| NEAR · iShares U.S. ETF Trust | 0,00% | 140 000 SH | 9 września 2026 | Dziennie |
| DFLV · Dimensional ETF Trust | 0,00% | 377 NS | 31 lipca 2026 | N-PORT |
| IXUS · iShares Trust | 0,00% | 22 623 SH | 11 września 2026 | Dziennie |
| VXUS · VANGUARD STAR FUNDS | 0,00% | 664 961 SH | 19 sierpnia 2026 | Dziennie |
| VSGX · VANGUARD WORLD FUND | 0,00% | 8 805 SH | 19 sierpnia 2026 | Dziennie |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | 15 lipca 2026 | Dziennie |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| ISCB · iShares Trust | · | 2 146 SH | 11 września 2026 | Dziennie |
| ISCV · iShares Trust | · | 10 576 SH | 11 września 2026 | Dziennie |
| SMLF · iShares Trust | · | 18 703 SH | 11 września 2026 | Dziennie |
CRL Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 23 analityków
KUP
Średni cel
$322.00
+11,0%
6 26,1%
Mocne kupno
11 47,8%
Kup
6 26,1%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
15 analityków · 2026-10-02Średnia cel $305.00 +5,1%
Teraz
Aktualna cena $290.19
Niski$145.00
Średnia$305.00
Wysoki$357.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| TECH | $11.03B | 60.9 | -0.38% | 15.0% | 9.0% | 65.8% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | · |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| BIO | · | · | · | · | · | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Bio-Techne przejmuje 477. miejsce od Charles River Laboratories International
Nasdaq · 3 miesiące temu
Podsumowanie Q1 konferencji z wynikami finansowymi Charles River Laboratories International
Yahoo Finance · 4 miesiące, 3 tygodnie temu
Tokenizowane kryptowalutowe obligacje skarbowe USA zbliżają się do 14 miliardów dolarów, a Circle i BlackRock prowadzą wzrost
Yahoo Finance · 5 miesięcy, 2 tygodnie temu
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 5, 2026